Published Date:2021-09-04 Original Link:https://www.onenessbio.com/en/news_detail56_2.htm No 2 Date of announcement 2021/09/04 Time of announcement 12:23:26 Subject The data of the Phase 3 international multicenter clinical trial and the mechanism of action of Fespixon (ON101) have been published by JAMA Network Open To which item it meets paragraph 53 Date of events 2021/09/03 Statement ...Read More
Published Date:2021-09-04 Original Link:https://www.onenessbio.com/en/news_detail55_2.htm No 1 Date of announcement 2021/09/04 Time of announcement 00:51:50 Subject Oneness decided not to proceed with FB704A phase 2 IND application in patients with severe COVID-19 based on strategic consideration To which item it meets paragraph 10 Date of events 2021/09/03 Statement 1.Product:FB704A 2.Mass production date:NA 3.Effect on...Read More
Published Date:2021-09-02 Original Link:https://www.onenessbio.com/en/news_detail54_2.htm No 1 Date of announcement 2021/09/02 Time of announcement 17:24:08 Subject Oneness Biotech Co., LTD receives a Japanese patent on OB318, a new drug in development for liver cancer. To which item it meets paragraph 53 Date of events 2021/09/02 Statement 1.Date of occurrence of the event:2021/09/02 2.Company name:ONENESS...Read More
Published Date:2021-08-10 Original Link:https://www.onenessbio.com/en/news_detail53_2.htm No 1 Date of announcement 2021/08/09 Time of announcement 17:42:02 Subject Oneness Biotech Co., LTD receives a Chinese patent on OB318, a new drug in development for liver cancer. To which item it meets paragraph 53 Date of events 2021/08/09 Statement 1.Date of occurrence of the event:2021/08/09 2.Company name:ONENESS...Read More
Published Date:2021-08-06 Original Link:https://www.onenessbio.com/en/news_detail52_3.htm No 3 Date of announcement 2021/08/06 Time of announcement 19:03:38 Subject A Chinese patent on the producing of recombinant glycoproteins with modified glycosylation was granted. To which item it meets paragraph 53 Date of events 2021/08/06 Statement 1.Date of occurrence of the event:2021/08/06 2.Company name:ONENESS BIOTECH CO., LTD. 3.Relationship to...Read More
Published Date:2021-07-21 Original Link:https://www.onenessbio.com/en/news_detail51_3.htm No 1 Date of announcement 2021/07/21 Time of announcement 18:51:43 Subject Oneness Biotech Co., LTD. receives a Russian patent titled”TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code:ON101). To which item it meets paragraph 53 Date of events 2021/07/21 Statement 1.Date of occurrence of the event:2021/07/21 2.Company...Read More
Published Date:2021-06-23 Original Link:https://www.onenessbio.com/en/news_detail49_3.htm No 1 Date of announcement 2021/06/23 Time of announcement 17:42:29 Subject Oneness announces the information about the investor’s conference of 2021 Q2. To which item it meets paragraph 12 Date of events 2021/06/28 Statement 1.Date of institutional investor conference:2021/06/28 2.Time of institutional investor conference:15:00 (GMT+8) 3.Location of institutional investor...Read More
Published Date:2021-06-16 Original Link:https://www.onenessbio.com/en/news_detail48_3.htm No 1 Date of announcement 2021/06/16 Time of announcement 23:43:02 Subject Oneness Bio will hold the launch event and the medical symposium of Fespixon, the new drug for treating DFUs To which item it meets paragraph 12 Date of events 2021/07/04 Statement 1.Date of institutional investor conference:2021/07/04 2.Time of...Read More
Published Date:2021-06-10 Original Link:https://www.onenessbio.com/en/news_detail47_3.htm No 1 Date of announcement 2021/06/10 Time of announcement 19:50:29 Subject Oneness Biotech and Taiwan CDE signed the agreement of regulatory science consultation and guidance on an indicator project in COVID-19 for FB704A. To which item it meets paragraph 53 Date of events 2021/06/10 Statement 1.Date of occurrence of...Read More
